SEC Form 4 · accession 0001764013-26-000073
Immunovant, Inc. · IMVT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Van Tuyl
Officer — Chief Legal Officer
Period of report
Jun 26, 2026
Accepted (ET)
Jun 26, 2026 · 7:45 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001764013
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 26, 2026 | M | 17,824 | $15.20 | A | 198,421 | D | |
| Common StockF1 | Jun 26, 2026 | S | 14,982 | $38.19 | D | 183,439 | D | |
| Common StockF2 | Jun 26, 2026 | S | 2,842 | $38.96 | D | 180,597 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $15.20 | Jun 26, 2026 | M | 17,824 | D | — | Apr 1, 2035 | Common Stock | 17,824 | 53,707 | D |
Explanation of responses
- F1The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 - $38.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.82 - $39.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F3Award of stock options to purchase Common Shares with a grant date of April 1, 2025. The shares underlying the option vest as to 25% on April 1, 2026, with the remainder vesting in 36 successive substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date.